Subcutaneous Therapy Improves Inflammatory Bowel Disease Treatment
mrr5831
Subcutaneous delivery of an anti-TNF inhibitor therapy improved remission rates compared to placebo in patients with moderate-to-severe Crohn’s disease and ulcerative colitis who previously completed intravenous anti-TNF therapy, according to clinical trial results published in the journal Gastroenterology. The post Subcutaneous Therapy Improves Inflammatory Bowel Disease Treatment appeared first on News Center .